# Viva Ventures Biotech Fund

> Viva Ventures Biotech Fund is a VC fund in Hong Kong backing Biotechnology and Health Care. See 25 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hong Kong, Hong Kong
- Total investments: 25
- Last investment: Oct 2021
- Lead investor: 72%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/viva-ventures-biotech/
- Website: https://www.vivaventuresbiotech.com/

Viva Ventures Biotech Fund is a VC fund in Hong Kong focused on Biotechnology and Health Care. Supporting 0 to 1 (Idea to NewCo) Biotech Startups in Large Scale

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 52% |
| Health Care | 8 | 32% |
| Pharmaceutical | 5 | 20% |
| Medical | 4 | 16% |
| Life Science | 3 | 12% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 36% |
| Seed | 5 | 20% |
| Series C | 5 | 20% |
| Convertible Note | 2 | 8% |
| Series B | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 48% |
| China | 3 | 12% |
| Belgium | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Arthrosi Therapeutics | Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development. The company was founded in 2017 and based in Laguna Hills, California. | $14.3M | Series C | Oct 22, 2021 |  |
| Basking Biosciences | Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage. |  | Seed | Aug 18, 2021 |  |
| Riparian Pharmaceuticals | Riparian Pharmaceuticals is an early stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics. The company develops medical therapies designed to treat cardiovascular and inflammatory diseases. The company is based in Boston Massachusetts. |  | Series A | Apr 01, 2021 |  |
| Seraxis | Seraxis is a private biotechnology company launched in March 2013. Incorporated in Singapore and the United States, their GMP lab is located in Germantown, Maryland. Seraxis team of scientists developed novel cell and encapsulation technologies. Their main goal is to bring a practical cell therapy for insulin-dependent diabetes to the clinic andprovide a long term cure to patients that does not require the use of immuno-suppression.Their corporate structure and strategy is designed to achieve that goal as quickly as possible, while bringing maximum value to their shareholders. | $40M | Series C | Feb 09, 2021 |  |
| Blue Oak Pharmaceuticals | Blue Oak Pharmaceuticals is a pharmaceutical company that is committed to finding the next generation of drugs for brain disorders. They believe that first-in-class drugs will be discovered by integrating novel, custom-designed privileged chemotypes with validated in vivo systems neurobiology assays and brain circuit imaging.Blue Oak drug huntersare experts in the systems neurobiology of brain disorders, medicinal chemistry, and informatics. Their productivity integrates a “global research team” that integrates established partners with cutting-edge technologies in behavioral profiling, synthetic chemistry, and brain imaging. They advance first-in-class clinical candidates to early phase proof-of-concept studies using translational medicine biomarkers for brain circuit activity.It was founded in 2016 and is headquartered in Waltham, Massachusetts. | $9M | Series A | Feb 01, 2021 |  |
| Clues Therapeutics Inc. | Integrate multi-technology target screening and drug discovery to improve innovation development efficiency. | $1.3M | Convertible Note | Jul 20, 2020 |  |
| Anji Pharmaceuticals | Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide. | $12M | Series A | Jul 01, 2020 |  |
| Sisu Pharma | Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the second most common cancer in men worldwide and there were over 1.3 million new cases of the disease globally in 2018. There are several treatments available for Prostate Cancer but none are curative and prolongedtreatment inevitably results in resistance and death. Sisu Pharma’s proprietary technology specifically targets a key protein that is critical to the survival and spread of advanced Prostate Cancer, providing desperately needed treatment for patients with no remaining options. | $1.7M | Seed | Jun 30, 2020 |  |
| Diagon, Inc. | Technology for generation and transplantation of Human Islet-like organoids. | $5M | Convertible Note | May 18, 2020 |  |
| Proviva Therapeutics, Inc | Prodrug design platform for cytokines and other fusion proteins |  | Seed | Jan 02, 2020 |  |

10 of 25 investments shown.

## Co-investors
- JMCR Partners — VC Fund, 19 deals together
- [Viva BioInnovator](https://shizune.co/investors/profile/viva-biotech) — VC Fund, 7 deals together
- Beida Biomedical Industry Fund — VC Fund, 2 deals together
- [City Hill Ventures](https://shizune.co/investors/profile/city-hill-ventures) — VC Fund, 2 deals together
- [JDRF T1D Fund](https://shizune.co/investors/profile/jdrf-t1d-fund) — VC Fund, 2 deals together
- [Ming Bioventures](https://shizune.co/investors/profile/ming-bioventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Viva Ventures Biotech Fund invest in?

Viva Ventures Biotech Fund invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Viva Ventures Biotech Fund last invest?

The most recent investment recorded for Viva Ventures Biotech Fund closed in Oct 2021. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co